What to expect with ROCKLATAN® and RHOPRESSA®

ONCE-DAILY rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

ONCE-DAILY rhopressa® (netarsudil ophthalmic solution) 0.02%

Your doctor has prescribed one of these eye drops to lower the pressure in your eye and help reduce the risk of vision loss due to glaucoma. Here are some tips to help you get the best out of your medicine.

- **Once daily at night**
  Take your medicine once a day, only at night. Keep bottle in the refrigerator until opened.
- **Possible side effects**
  Visible eye redness occurred in clinical trials for Rocklatan® and Rhopressa®. The condition occurred in 53% of patients taking Rhopressa® and 59% of patients taking Rocklatan®, and it was often mild and occurred occasionally. Eye redness did not tend to get worse with continued use.
  PLEASE SEE IMPORTANT SAFETY INFORMATION ON THE REVERSE SIDE.
- **Tell your doctor**
  If eye redness is a concern for you, please contact your doctor immediately. Do not stop taking your drops unless your doctor tells you to stop. Contact your doctor immediately if you experience any sudden change in your vision.
- **If the pharmacy wants to switch you to another medication**
  Ask if the switch request was mandated by your prescription insurance plan. Eligible commercially insured patients may pay as little as $25 for a 30-day or 90-day prescription with our Savings Offer.* Ask your doctor how, or visit Rhopressa.com or Rocklatan.com for your Savings Offer now.
- **Keep your appointments with your eye doctor**
  Make sure to keep your next appointment with your eye doctor so you can review your progress with your medicine.

*Restrictions apply. Patients with federal or state prescription coverage, such as Medicare or Medicaid, are not eligible.

ROCKLATAN® AND RHOPRESSA® INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and RHOPRESSA® (netarsudil ophthalmic solution) 0.02% are prescription medications for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

Please see reverse side for IMPORTANT SAFETY INFORMATION.

To learn more, please visit www.Rocklatan.com and www.Rhopressa.com

ROCKLATAN® AND RHOPRESSA® INDICATIONS AND USAGE

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and RHOPRESSA® (netarsudil ophthalmic solution) 0.02% are prescription medications for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

ROCKLATAN® AND RHOPRESSA® DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening.

The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

ROCKLATAN® IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

ROCKLATAN® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as ROCKLATAN® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

ROCKLATAN® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

ROCKLATAN® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

ROCKLATAN® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using ROCKLATAN®. Contact lenses can be reinserted 15 minutes following administration of ROCKLATAN®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with ROCKLATAN®.

Adverse Reactions

The most common side effect for ROCKLATAN® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%).

Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

For full Prescribing Information for ROCKLATAN® Solution, please visit Rocklatan.com

RHOPRESSA® IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact Lenses: Contact lenses should be removed prior to using RHOPRESSA® and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily were red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the outer surface of the eye, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The small deposits on the outer surface of the eye seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.

Please see full RHOPRESSA® Prescribing Information at Rhopressa.com

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Reference: 1. Data on file, Aerie Pharmaceuticals, Inc.